BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 10197036)

  • 1. Recent developments in tetracycline antibiotics.
    Sum PE; Sum FW; Projan SJ
    Curr Pharm Des; 1998 Apr; 4(2):119-32. PubMed ID: 10197036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.
    Testa RT; Petersen PJ; Jacobus NV; Sum PE; Lee VJ; Tally FP
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2270-7. PubMed ID: 8285606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two investigational glycylcyclines, DMG-DMDOT and DMG-MINO. Antimicrobial activity studies against gram-positive species.
    Johnson DM; Jones RN
    Diagn Microbiol Infect Dis; 1996 Jan; 24(1):53-7. PubMed ID: 8988765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).
    Petersen PJ; Jacobus NV; Weiss WJ; Sum PE; Testa RT
    Antimicrob Agents Chemother; 1999 Apr; 43(4):738-44. PubMed ID: 10103174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.
    Projan SJ
    Pharmacotherapy; 2000 Sep; 20(9 Pt 2):219S-223S; discussion 224S-228S. PubMed ID: 11001329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The glycylcyclines: a comparative review with the tetracyclines.
    Zhanel GG; Homenuik K; Nichol K; Noreddin A; Vercaigne L; Embil J; Gin A; Karlowsky JA; Hoban DJ
    Drugs; 2004; 64(1):63-88. PubMed ID: 14723559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
    Sum PE; Petersen P
    Bioorg Med Chem Lett; 1999 May; 9(10):1459-62. PubMed ID: 10360756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N,N-dimethylglycyl-amido derivative of minocycline and 6-demethyl-6-desoxytetracycline, two new glycylcyclines highly effective against tetracycline-resistant gram-positive cocci.
    Goldstein FW; Kitzis MD; Acar JF
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2218-20. PubMed ID: 7811053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline.
    Honeyman L; Ismail M; Nelson ML; Bhatia B; Bowser TE; Chen J; Mechiche R; Ohemeng K; Verma AK; Cannon EP; Macone A; Tanaka SK; Levy S
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7044-53. PubMed ID: 26349824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors.
    Chopra I
    Drug Resist Updat; 2002; 5(3-4):119-25. PubMed ID: 12237079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.
    Gales AC; Jones RN
    Diagn Microbiol Infect Dis; 2000 Jan; 36(1):19-36. PubMed ID: 10744364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecyclin--the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline.
    Felmingham D
    J Chemother; 2005 Aug; 17 Suppl 1():5-11. PubMed ID: 16285353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case studies in current drug development: 'glycylcyclines'.
    Sum PE
    Curr Opin Chem Biol; 2006 Aug; 10(4):374-9. PubMed ID: 16807065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines.
    Tuckman M; Petersen PJ; Projan SJ
    Microb Drug Resist; 2000; 6(4):277-82. PubMed ID: 11272255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to new glycylcyclines in comparison with those to older tetracyclines.
    Kenny GE; Cartwright FD
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2628-32. PubMed ID: 7872759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tigecycline - how powerful is it in the fight against antibiotic-resistant bacteria?
    Seputiene V; Povilonis J; Armalyte J; Suziedelis K; Pavilonis A; Suziedeliene E
    Medicina (Kaunas); 2010; 46(4):240-8. PubMed ID: 20571291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tigecycline.
    Pankey GA
    J Antimicrob Chemother; 2005 Sep; 56(3):470-80. PubMed ID: 16040625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of two glycylcyclines against gram-positive bacteria.
    Eliopoulos GM; Wennersten CB; Cole G; Moellering RC
    Antimicrob Agents Chemother; 1994 Mar; 38(3):534-41. PubMed ID: 8203851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.